• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    ENDRA Life Sciences Inc. filed SEC Form 8-K: Leadership Update, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Submission of Matters to a Vote of Security Holders, Other Events, Financial Statements and Exhibits

    8/9/24 8:02:42 AM ET
    $NDRA
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care
    Get the next $NDRA alert in real time by email
    ndra_8k.htm
    0001681682false--12-31734335-046800016816822024-08-052024-08-05iso4217:USDxbrli:sharesiso4217:USDxbrli:shares

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, DC 20549

     

    FORM 8-K

    CURRENT REPORT

    Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934

     

    Date of Report (Date of earliest event reported) August 5, 2024

     

    ENDRA Life Sciences Inc. 

    (Exact name of registrant as specified in its charter)

     

    Delaware 

     

    001-37969

     

    26-0579295

    (State or other jurisdiction of incorporation)

     

    (Commission File Number)

     

    (IRS Employer Identification No.)

     

    3600 Green Court, Suite 350 Ann Arbor, MI

     

    48105

    (Address of principal executive offices)

     

    (Zip Code)

     

     

     

    Registrant's telephone number, including area code

     

    (734) 335-0468

     

    ______________________________________________

    (Former name or former address, if changed since last report)

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

     

    ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

    ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

    ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

    ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

     

    Securities registered pursuant to Section 12(b) of the Act:

     

    Title of each class

    Trading Symbol(s)

    Name of each exchange on which registered

    Common stock, par value $0.0001 per share

    NDRA

    The Nasdaq Stock Market LLC

     

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

     

    Emerging growth company ☐

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

     

     

     

     

    Item 5.02 Departure of Directors or Certain Officers; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

     

    On August 5, 2024, Irina Pestrikova notified ENDRA Life Sciences Inc. (“ENDRA” or the “Company”) of her resignation as the Company’s Senior Director, Finance, effective August 7, 2024.  Ms. Pestrikova’s resignation is not in connection with any disagreement relating to the Company’s operations, policies, or practices. Ms. Pestrikova may provide consulting services to the Company after her resignation, as desired and agreed to between Ms. Pestrikova and Company management, in order to assist with the transitional matters.

     

    On August 8, 2024, the Company’s Board of Directors (the “Board of Directors”) appointed Richard Jacroux as Head of Finance. Mr. Jacroux will serve as the Company’s principal financial officer in such role.

     

    Mr. Jacroux, age 57, has been a consultant for the Company since March 2024. Mr. Jacroux has over 20 years of experience in financial management and accounting. Mr. Jacroux began his career at Ernst & Young LLP and has held the role of Chief Financial Officer at several technology companies, including IUNU and Buddy Platform, Ltd. Mr. Jacroux is the founder of Impact Solve, LLC, an accounting and fractional chief financial officer service firm. In addition, he is an adjunct professor in the Business Department at the University of Washington. Mr. Jacroux received a BA in business administration and accounting from the University of Washington, and an MBA from the Kellogg School of Management. Mr. Jacroux receives a base monthly fee of $8,650 plus expenses in respect of his services to the Company.

     

    There are no family relationships between Mr. Jacroux and any director or executive officer of the Company, and he has no direct or indirect material interest in any transaction required to be disclosed pursuant to Item 404(a) of Regulation S-K.

     

    Item 5.03 Amendment to Articles of Incorporation or Bylaws; Change in Fiscal Year

     

    At the 2024 Annual Meeting of the Company’s Stockholders held on August 6, 2024 (the “Annual Meeting”), the Company’s stockholders approved and adopted a Certificate of Amendment to the Company’s Fourth Amended and Restated Certificate of Incorporation (the “Certificate of Incorporation”) to increase the number of authorized shares of Company’s common stock, par value $0.0001 (the “Common Stock”), from 80,000,000 shares to 1,000,000,000 shares (the “Charter Amendment”). The Charter Amendment was filed with the Secretary of State of the State of Delaware on August 8, 2024 and was effective upon filing.

     

    This above description is a summary of the Charter Amendment and is qualified in its entirety by reference to the full text of the Charter Amendment, a copy of which is filed as Exhibit 3.1 to this Current Report on Form 8-K and incorporated by reference herein.

     

    Item 5.07 Submission of Matters to a Vote of Security Holders

     

    The certified results of the matters voted upon at the Annual Meeting, which are more fully described in the definitive proxy statement for the Annual Meeting as filed with the Securities and Exchange Commission on June 25, 2024, are as follows:

     

    Proposal 1 – The Company’s stockholders elected the five directors nominated by the Company’s Board of Directors to serve until the next annual meeting of stockholders and the election of their successors:

     

     

     

    For

     

     

    Withheld

     

     

    Broker Non-Votes

     

    Francois Michelon

     

     

    11,504,116

     

     

     

    1,473,189

     

     

     

    14,685,263

     

    Louis J. Basenese

     

     

    11,417,842

     

     

     

    1,559,463

     

     

     

    14,685,263

     

    Anthony DiGiandomenico

     

     

    11,391,809

     

     

     

    1,585,496

     

     

     

    14,685,263

     

    Michael Harsh

     

     

    11,404,110

     

     

     

    1,573,195

     

     

     

    14,685,263

     

    Alexander Tokman

     

     

    11,614,570

     

     

     

    1,362,735

     

     

     

    14,685,263

     

     

     
    2

     

     

    Proposal 2 – The Company’s stockholders approved, on an advisory basis, the compensation paid to the Company’s named executive officers:

     

    For

     

    Against

     

    Abstain

     

    Broker Non-Votes

    9,527,006

     

    3,363,535

     

    86,764

     

    14,685,263

     

    Proposal 3 – The Company’s stockholders approved the issuance of shares of Common Stock, upon the exercise of certain warrants issued in the Company’s registered public offering that closed on June 5, 2024, and certain adjustment provisions included in such warrants:

     

    For

     

    Against

     

    Abstain

     

    Broker Non-Votes

    9,476,409

     

    3,455,013

     

    45,883

     

    14,685,263

     

    Proposal 4 – The Company’s stockholders approved the Charter Amendment to increase the authorized number of shares of Common Stock from 80,000,000 shares to 1,000,000,000 shares:

     

    For

     

    Against

     

    Abstain

     

    Broker Non-Votes

    8,718,055

     

    4,235,340

     

    23,910

     

    14,685,263

     

    Proposal 5 – The Company’s stockholders approved a Certificate of Amendment to the Certificate of Incorporation to effect a reverse stock split of the shares of the Common Stock at a stock split ratio between 1-for-20 and 1-for-50, inclusive (the “Reverse Stock Split”), with the ultimate ratio to be determined by the Company’s Board of Directors in its sole discretion:

     

    For

     

    Against

     

    Abstain

     

    20,924,186

     

    6,631,019

     

    107,636

     

     

    Proposal 6 – The Company’s stockholders ratified the appointment of RBSM LLP by the Audit Committee of the Board of Directors as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2024:

     

    For

     

    Against

     

    Abstain

     

    26,096,855

     

    1,335,168

     

    230,545

     

      

    Item 8.01 Other Events.

     

    On August 8, 2024, following the Annual Meeting, the Board of Directors approved a ratio of 1-for-50 for the Reverse Stock Split.

     

     
    3

     

     

    Item 9.01 Financial Statements and Exhibits.

     

    (d) Exhibits

     

    Exhibit No.

     

    Description

    3.1

     

    Certificate of Amendment to the Company’s Fourth Amended and Restated Certificate of Incorporation, effective August 8, 2024

    104

     

    Cover Page Interactive Data File (embedded within the Inline XBRL document)

     

     

    4

     

      

    SIGNATURE

     

    Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     

     

    ENDRA Life Sciences Inc.

     

    August 9, 2024

     

     

     

    By:

    /s/ Francois Michelon

     

     

    Name:

    Francois Michelon

     

     

    Title:

    President and Chief Executive Officer

     

     

     
    5

     

    Get the next $NDRA alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $NDRA

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $NDRA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Executive Officer Tokman Alexander Y was granted 26,921 shares, increasing direct ownership by 36% to 101,926 units (SEC Form 4)

    4 - ENDRA Life Sciences Inc. (0001681682) (Issuer)

    3/4/26 9:48:18 PM ET
    $NDRA
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Chief Financial Officer Jacroux Richard was granted 13,461 shares, increasing direct ownership by 67% to 33,461 units (SEC Form 4)

    4 - ENDRA Life Sciences Inc. (0001681682) (Issuer)

    3/4/26 9:48:01 PM ET
    $NDRA
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Director Digiandomenico Anthony was granted 60,324 shares, increasing direct ownership by 79% to 136,589 units (SEC Form 4)

    4 - ENDRA Life Sciences Inc. (0001681682) (Issuer)

    1/23/26 7:44:04 PM ET
    $NDRA
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $NDRA
    SEC Filings

    View All

    ENDRA Life Sciences Inc. filed SEC Form 8-K: Leadership Update, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits

    8-K - ENDRA Life Sciences Inc. (0001681682) (Filer)

    12/12/25 8:31:26 PM ET
    $NDRA
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    ENDRA Life Sciences Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits

    8-K - ENDRA Life Sciences Inc. (0001681682) (Filer)

    11/28/25 4:23:04 PM ET
    $NDRA
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    SEC Form SCHEDULE 13D filed by ENDRA Life Sciences Inc.

    SCHEDULE 13D - ENDRA Life Sciences Inc. (0001681682) (Subject)

    11/26/25 4:30:31 PM ET
    $NDRA
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $NDRA
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    ENDRA's TAEUS® Liver Device Demonstrates High-Level Consistency in Clinical Study, Delivering MRI-Level Results at the Point of Patient Care

    Achieved Intraclass Correlation Coefficient (ICC) of 0.89 with standard error of measurement (SEM) of 3.3% using independent operators ENDRA Life Sciences Inc. (NASDAQ:NDRA) ("ENDRA" or the "Company"), a pioneer in thermoacoustic biomarker imaging for the early detection and monitoring of steatotic liver disease (SLD), today announced favorable results from a clinical study evaluating the measurement consistency of its TAEUS® Liver device. The study demonstrated the device's robust intra-user repeatability and inter-user reproducibility, essential factors for long-term monitoring of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD), which now affects approximately 30% of ad

    2/26/26 8:00:00 AM ET
    $NDRA
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    ENDRA's TAEUS® Liver Matches MRI-PDFF Performance at Key Clinical Thresholds, Positioning Device for MASLD/MASH Trial Use

    Feasibility study data at 12-22% liver fat cutoffs validate TAEUS as a potential low-cost, point-of-care alternative to MRI-PDFF for patient stratification and trial monitoring ENDRA Life Sciences Inc. (NASDAQ:NDRA) ("ENDRA" or the "Company"), a pioneer in thermo-acoustic biomarker imaging for early detection and monitoring of steatotic liver disease (SLD), today announced new results from its 2025 TAEUS Liver device feasibility study demonstrating that TAEUS' thermo-acoustic fat fraction (TAFF) measurement closely tracks the MRI-PDFF gold standard at critical liver fat fraction (LFF) thresholds of 12-17% and 20-22%. These thresholds separate mild, moderate and severe disease, are widely

    12/4/25 8:00:00 AM ET
    $NDRA
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    ENDRA Feasibility Study Demonstrates TAEUS® Accurately Quantifies Liver Fat Fraction, a Key MASLD/MASH Biomarker

    TAEUS Liver demonstrates strong agreement with the industry's imaging gold standard, MRI‑PDFF, across the full spectrum of steatotic liver disease and patient BMI ENDRA Life Sciences Inc. (NASDAQ:NDRA) ("ENDRA" or the "Company"), a pioneer in biomarker imaging technologies for the early detection and monitoring of metabolic dysfunction-associated liver disease ("MASLD") and metabolic dysfunction-associated steatohepatitis ("MASH"), today announces encouraging preliminary results from a single-site clinical feasibility study evaluating its improved TAEUS Liver device for quantifying liver fat fraction, which is a key biomarker of steatotic liver disease ("SLD"). The preliminary study res

    11/20/25 8:00:00 AM ET
    $NDRA
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $NDRA
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Amendment: Market maker/broker-dealer Ubs Group Ag bought 0 shares (SEC Form 4)

    4/A - ENDRA Life Sciences Inc. (0001681682) (Issuer)

    9/5/24 3:28:10 PM ET
    $NDRA
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Large owner Ubs Group Ag bought $2,052 worth of shares (3,715 units at $0.55) (SEC Form 4)

    4 - ENDRA Life Sciences Inc. (0001681682) (Issuer)

    8/29/24 4:30:01 PM ET
    $NDRA
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $NDRA
    Leadership Updates

    Live Leadership Updates

    View All

    ENDRA Life Sciences Appoints Irina Pestrikova as Senior Director of Finance, Announces Departure of CFO David Wells

    ANN ARBOR, MI / ACCESSWIRE / June 15, 2021 / ENDRA Life Sciences Inc. (NASDAQ:NDRA), a pioneer of Thermo Acoustic Enhanced UltraSound (TAEUS®), announced the appointment of Irina Pestrikova as Senior Director of Finance and Principal Financial Officer. In this new position, Ms. Pestrikova will assume all day-to-day responsibilities previously performed by ENDRA's Chief Financial Officer David Wells, who will leave the Company effective June 18, 2021 to pursue another opportunity.Ms. Pestrikova has supported ENDRA since 2014 and has been actively involved in ENDRA's financial planning and analysis, accounting and SEC reporting functions. Previously, Ms. Pestrikova was a financial analyst at a

    6/15/21 8:35:00 AM ET
    $NDRA
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $NDRA
    Financials

    Live finance-specific insights

    View All

    ENDRA Life Sciences Reports Fourth Quarter and Full-Year 2024 Financial Results and Provides a Business Update

    ENDRA Life Sciences Inc. (NASDAQ:NDRA), a pioneer of Thermo-Acoustic Enhanced UltraSound (TAEUS®), today reported financial results for the fourth quarter and full-year ended December 31, 2024, and provided a business update. Business Update ENDRA made significant progress against many of the new initiatives discussed during the Company's August 22, 2024, conference call to advance its TAEUS Liver device along the development and regulatory process. In addition, ENDRA separately announced today a revamped strategy for TAEUS as a biomarker solution for the early detection and management of metabolic diseases in patients being treated with glucagon-like peptide-1 (GLP-1) drugs. ENDRA's prog

    3/31/25 8:00:00 AM ET
    $NDRA
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    ENDRA Life Sciences Regains Compliance with Nasdaq Minimum Bid Price Requirement

    ENDRA Life Sciences Inc. (NASDAQ:NDRA), an innovator of Thermo Acoustic Enhanced UltraSound (TAEUS®), today announced that it has regained compliance with the minimum bid price requirement set forth by The Nasdaq Stock Market LLC ("Nasdaq"). On November 21, 2024, the Company received notification from the Nasdaq Listing Qualifications Department confirming its compliance with Listing Rule 5550(a)(2), thereby meeting Nasdaq's maintenance requirements for listing. "Now that we have regained compliance with Nasdaq's listing requirements, we can focus all our efforts on making progress on our new transformational business strategies, which we reviewed during our August 22nd conference call,

    11/22/24 8:00:00 AM ET
    $NDRA
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    ENDRA Life Sciences Reschedules Second Quarter Conference Call to August 22, 2024

    ENDRA Life Sciences Inc. ("ENDRA") (NASDAQ:NDRA), a pioneer of Thermo Acoustic Enhanced UltraSound (TAEUS®), today announced that it will host a conference call and webcast beginning at 4:30 p.m. Eastern time on August 22, 2024, to discuss quarterly results, provide an update on recent corporate developments and answer questions. This call was previously scheduled for August 14, 2024. The Company will file its quarterly report on form 10-Q with the SEC as regularly scheduled in the coming days. A press release summarizing its financial and operating results for the second quarter ending on June 30, 2024, will be issued on the day of the call. Participants are encouraged to pre-register

    8/13/24 4:05:00 PM ET
    $NDRA
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $NDRA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by ENDRA Life Sciences Inc.

    SC 13G - ENDRA Life Sciences Inc. (0001681682) (Subject)

    6/14/24 4:01:26 PM ET
    $NDRA
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    SEC Form SC 13G filed by ENDRA Life Sciences Inc.

    SC 13G - ENDRA Life Sciences Inc. (0001681682) (Subject)

    6/14/24 8:00:02 AM ET
    $NDRA
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    SEC Form SC 13G filed by ENDRA Life Sciences Inc.

    SC 13G - ENDRA Life Sciences Inc. (0001681682) (Subject)

    3/10/23 12:18:14 PM ET
    $NDRA
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care